ICES 13

Drug Profile

ICES 13

Alternative Names: ICES-13; Skeletal muscle-derived cells; SMDCs

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovacell Biotechnologie GmbH
  • Class Cell therapies; Urologics
  • Mechanism of Action Cell replacements; Cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stress incontinence

Most Recent Events

  • 13 Sep 2017 ICES 13 is still in clinical development for Stress incontinence in Austria (Innovacell Biotechnologie AG website, September 2017)
  • 20 Apr 2015 Phase-III development is ongoing in Germany, Czech Republic, Poland, Bulgaria, Austria, Italy and United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top